Diagnostic value of microRNAs for malignant pleural mesothelioma: A mini‐review

• Published in: Thoracic cancer Vol. 12; no. 1; pp. 8 - 12
• Main Authors: Han, Yan‐Qiu, Xu, Shang‐Cheng, Zheng, Wen‐Qi, Hu, Zhi‐De
• Format: Journal Article
• Language: English
• Published: Melbourne John Wiley & Sons Australia, Ltd 01.01.2021; John Wiley & Sons, Inc; Wiley
• Subjects: Accuracy; Asbestos; Biomarkers; Cancer; Diagnosis; Epidemiology; Gene expression; Genetic transcription; malignant pleural mesothelioma; Medical prognosis; Mesothelioma; MicroRNA; MicroRNAs; Mini Review; Pleural effusion; Prognosis; Regression analysis; review; malignant pleural mesothelioma; microRNA; Diagnosis; review
• ISSN: 1759-7706; 1759-7714; 1759-7714
• DOI: 10.1111/1759-7714.13746

Malignant pleural mesothelioma (MPM) is a type of cancer originating from the pleura with high aggressiveness and poor prognosis. A timely diagnosis is crucial to improve its prognosis. Laboratory biomarkers have significant advantages of reduced invasiveness, low cost, and are observer‐independent, and therefore represent a promising diagnostic tool for MPM. MicroRNA is a family of non‐coding RNA that regulates gene expression at the post‐transcriptional level. Accumulated studies showed that microRNA, either in tissue, circulating, and body fluid, has potential diagnostic value for various disorders. Here, we reviewed the diagnostic value of microRNA for MPM. Malignant pleural mesothelioma (MPM) is a type of cancer originating from the pleura with high aggressiveness and poor prognosis, Laboratory biomarkers have significant advantages of reduced invasiveness, low cost, and are observer‐independent, and therefore represent a promising diagnostic tool for MPM. Here, we reviewed the diagnostic value of microRNA for MPM.